ARIAD Announces Full Enrollment in Phase 2 ALTA Trial of Brigatinib

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/26/2026

1. SPY
2. AKAM
3. COST
4. META
5. ZS
6. NVDA
7. AWK
8. DRI
9. ULS
10. CRL

Go back to ARIAD Announces Full Enrollment in Phase 2 ALTA Trial of Brigatinib
Ariad Pharmaceuticals, Inc. (NYSE: ARIA) Delayed: 26.36 +0.19 (0.73%)
Previous Close $26.17    52 Week High $14.34 
Open $26.36    52 Week Low $4.37 
Day High $26.36    P/E N/A 
Day Low $26.36    EPS $-1.45 
Volume 63